Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Third party request |
| Strategy: | Combo: Protein & vector vaccines |
| Study Type: | Phase III |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2015-10-20 |
| Study Made Public: | 2016-07-20 |
Title
Neutralizing antibody responses and linear epitope specificity in RV305
Description
CAVD 526 (TP 13) is an immunogenicity study of neutralizing antibody responses and linear epitope specificity in RV305 subjects.
Sign in to see full information about this study and to download study data.
Products
ALVAC (vCP1521) AIDSVAX B/E Saline (non-specific) Placebo ALVAC Placebo AIDSVAX B/EIntegrated data
NAb
Non-integrated data
No non-integrated data is available for this study.